Operating cash flow of $47.3M in 2026Q3 converted at a 1.00 OCF/NI ratio into $47.1M free cash flow (16.5% margin) with capex of just 0.1% of revenue, although $13.1M quarterly SBC (~4.6% of revenue) warrants scrutiny of cash earnings quality.
Kiniksa Pharmaceuticals International, plc (KNSA) cash flow statement — 10-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Cash from Operations | 198.84M | 25.69M | 25.69M | 13.3M | 5.81M | -126.3M | -136.53M | -158.37M | -81.01M | -50.22M | -21.87M |
| Operating CF Margin % | - | 3.79% | 6.07% | 4.92% | 2.64% | -327.67% | - | - | - | - | - |
| Operating CF Growth % | 421.35% | 0% | 93.14% | 129.05% | 104.6% | 7.5% | 13.79% | -95.49% | -61.32% | -129.66% | - |
| Net Income | 109.57M | -43.19M | -43.19M | 14.08M | 183.36M | -157.92M | -161.38M | -161.87M | -103.23M | -64.87M | -23.97M |
| Depreciation & Amortization | 2.95M | 1.55M | 1.7M | 2.34M | 2.4M | 2.35M | 2.4M | 2.07M | 286K | 28K | 22K |
| Stock-Based Compensation | 38.68M | 30.69M | 30.69M | 27.15M | 25.12M | 25.17M | 20.88M | 15.08M | 5.7M | 897K | 368K |
| Deferred Taxes | -1.11M | 8.13M | 8.13M | -33.79M | -185.5M | 11K | 4.36M | -3.16M | -978K | -197K | -46K |
| Other Non-Cash Items | 131.52M | -23.13M | 3.55M | 2.17M | 2.99M | 3.4M | 1.52M | 6.53M | -1.12M | -53K | 293K |
| Working Capital Changes | 19.43M | 51.63M | 24.81M | 1.35M | -22.57M | 689K | -4.32M | -17.02M | 18.33M | 13.93M | 1.76M |
| Change in Receivables | 20.96M | 26.13M | -20.46M | -950K | -16.33M | -3.91M | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | -66.63M | 4.76M | 4.76M | -9.52M | -17.92M | -3.67M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -8.49M | -6.31M | -6.31M | 347K | 6.03M | 1.37M | -4.97M | -4.71M | 8.82M | 1.01M | 119K |
| Cash from Investing | -314.87M | 37.67M | 37.67M | -29.56M | -8.08M | 128.63M | -23.44M | 49.21M | -239.2M | -69K | -3K |
| Capital Expenditures | -346K | -277K | -277K | -130K | -105K | -415K | -283K | -3.2M | -5.29M | -69K | -3K |
| CapEx % of Revenue | 0.04% | 0.04% | 0.07% | 0.05% | 0.05% | 1.08% | - | - | - | - | - |
| Acquisitions | 0 | 0 | 25K | 0 | 0 | 0 | 23.16M | -52.42M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -226.64M | 25K | 0 | 0 | 91K | -20M | -23.16M | 52.42M | -233.91M | 0 | 0 |
| Cash from Financing | 22.84M | 12.27M | 12.27M | 1.5M | 2.52M | 5.88M | 227.09M | 84.11M | 346.74M | 39.87M | 42.51M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | -918K | -7.73M | -4.98M | -2.21M | 3.42M | 5.88M | 228.22M | 83.11M | 350.02M | 39.87M | 42.5M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -918K | -7.73M | -4.98M | -2.21M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 23.76M | 20M | 17.25M | 3.7M | -901K | 0 | -1.14M | 1M | -3.28M | 0 | 10K |
| Net Change in Cash | -93.2M | 75.63M | 75.63M | -14.76M | 245K | 8.22M | 67.11M | -25.05M | 26.53M | -10.41M | 20.64M |
| Free Cash Flow | 197.2M | 25.41M | 25.41M | 13.17M | 5.7M | -146.71M | -136.81M | -161.57M | -86.3M | -50.29M | -21.87M |
| FCF Margin % | 20.85% | 3.75% | 6% | 4.87% | 2.59% | -380.64% | - | - | - | - | - |
| FCF Growth % | 93.84% | 0% | 92.94% | 130.99% | 103.89% | -7.23% | 15.32% | -87.22% | -71.62% | -129.94% | - |
| FCF per Share | 2.32 | 0.32 | 0.36 | 0.18 | 0.08 | -2.14 | -2.21 | -2.99 | -2.92 | -1.55 | -0.67 |
| FCF Conversion (FCF/Net Income) | 1.80x | 0.44x | -0.59x | 0.94x | 0.03x | 0.80x | 0.85x | 0.98x | 0.78x | 0.77x | 0.91x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 2M | 5.61M | 10.69M | 1.28M | 482K | 1.72M | 383K | 290K | 115K |
Quick answers to the most common questions about buying KNSA stock.
Kiniksa Pharmaceuticals International, plc (KNSA) generated $25.7M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Kiniksa Pharmaceuticals International, plc (KNSA) generated $25.4M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Kiniksa Pharmaceuticals International, plc (KNSA) spent $0.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Kiniksa Pharmaceuticals International, plc (KNSA) spent $7.7M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
SBC acceleration and cash idleness
Metrics are mathematically derived from official filings.
Cash Conversion Exceeds Reported Earnings
Kiniksa's operating cash flow has consistently exceeded net income across profitable quarters, with OCF/NI ratios reaching 3.80 in 2025Q4 and averaging above 1.5 since the 2025Q1 profitability inflection, according to quarterly financial statements, suggesting high-quality earnings with limited accrual distortion.
The divergence between operating cash flow and net income has been notably wide in several periods, most strikingly in 2025Q4 when $53.9M of OCF was generated against just $14.2M of net income—a 3.80x ratio driven by a combination of non-cash SBC, modest D&A, and a $19.4M working capital release. Even during the loss-making 2024Q3 quarter, OCF was nearly breakeven at -$2.2M despite a $12.7M net loss, indicating the cash dynamics were healthier than headline earnings suggested. The consistent OCF-over-NI pattern implies that reported profitability, while modest, understates the true cash-generating power of the ARCALYST franchise.
FCF Compounds Alongside Commercial Ramp
Free cash flow has expanded from $18.6M in 2024Q4 to $47.1M in 2026Q3, representing roughly 153% growth over seven quarters, with FCF margins ranging between 15% and 26%, as reported in Kiniksa's quarterly filings, indicating durable and compounding cash generation alongside ARCALYST's commercial ramp.
The FCF trajectory closely tracks ARCALYST revenue growth, rising from $18.6M in 2024Q4 to $53.3M in 2025Q4 before moderating to $47.1M in 2026Q3. The most recent quarter's 16.5% FCF margin sits below the 26.4% peak in 2025Q4, which was likely amplified by a $19.4M working capital release; stripping out WC swings suggests a more normalized underlying margin in the high-teens. Critically, every incremental dollar of ARCALYST revenue appears to translate to FCF at a high rate given the near-zero capital intensity, implying the cash trajectory should remain closely correlated with commercial execution.
Near-Zero Capital Intensity Amplifies Cash Yield
Capital expenditures have remained negligible at 0.1–0.4% of revenue over the last ten quarters, with quarterly capex never exceeding $671K, based on reported cash flow statements, confirming an asset-light commercial model that allows nearly all operating cash flow to convert to free cash flow.
Kiniksa's minimal capex is consistent with an outsourced manufacturing model typical of orphan drug commercial-stage companies, where the value concentrates in regulatory exclusivity and commercial infrastructure rather than physical assets. The D&A run-rate of $0.3–1.8M per quarter reinforces the absence of a meaningful fixed asset base, meaning depreciation is not a meaningful drag on reported earnings nor a signal of underinvestment. While this structure maximizes near-term FCF conversion, any pivot toward in-house manufacturing or major capital deployment for KPL-404 commercialization would represent a structural step-change that investors should monitor.
Cash Accumulates Without Shareholder Returns
Kiniksa has paid zero dividends and executed only minimal share repurchases across ten quarters of reported data, with quarterly buyback activity never exceeding $4.4M, as disclosed in SEC cash flow filings, suggesting management is retaining nearly all free cash flow for pipeline development and strategic optionality.
The absence of any dividend or meaningful buyback program over the reported period indicates management views retained cash as a strategic war chest—potentially for KPL-404 clinical investment, commercial expansion, or future business development. Given the near-zero debt profile (approximately 0.02% debt-to-equity), there is no deleveraging imperative, leaving organic pipeline investment or opportunistic M&A as the most likely cash deployment vectors. This posture is defensible during a platform transition phase, but as cumulative FCF builds toward an estimated $300M+ over the trailing ten quarters, investor expectations for capital return or disclosed deployment strategy may intensify.
SBC Ramp and Working Capital Noise Obscure Trends
Stock-based compensation has accelerated from $7.4M in 2024Q2 to $13.1M in 2026Q3, representing roughly 4.6% of quarterly revenue, while quarterly working capital swings have ranged from +$20.5M to -$10.1M, as reflected in Kiniksa's cash flow statements, collectively obscuring the true underlying cash generation trajectory.
The rising SBC is a genuine economic cost that inflates operating cash flow relative to economic earnings, and its acceleration—from $3.9M in 2025Q4 to $13.1M in 2026Q3—suggests equity compensation is becoming a more material component of the cost structure, potentially masking dilution in per-cash-flow metrics. More critically, the working capital line has been highly volatile (ranging from +$20.5M in 2024Q4 to -$10.1M in 2026Q2), making quarter-over-quarter OCF comparisons unreliable without normalization. Additionally, the Regeneron profit share is embedded within cost of revenue and represents a persistent, undisclosed-in-cash-flow-line outflow that structurally reduces the cash economics of the ARCALYST franchise below what the OCF line alone would suggest.